MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:28Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Statins]]
			[[Category:Lipid-lowering agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #12

2026-05-23T03:29:42Z

parser-claude batch MedTemplate pre-fill, Top 300 #12

New page

{{MedTemplate
| generic = Rosuvastatin
| brand = Crestor, Ezallor
| structure =
| classes = [[:Category:Statins|Statin]], [[:Category:Lipid-lowering_agents|Lipid-lowering agent]]
| uses = <vote slug="hyperlipidemia-use">Hyperlipidemia</vote>, <vote slug="cv-risk-reduction-use">Cardiovascular risk reduction</vote>, <vote slug="atherosclerosis-use">Atherosclerosis</vote>
| starting_dose = 10-20 mg PO once daily (5 mg in Asian ancestry, elderly, hypothyroidism, or strong CYP/SLCO1B1 interactions)
| preparations = 5, 10, 20, 40 mg tablets
| fda_max = 40 mg/d (rarely needed; 40 mg restricted to patients not at goal on 20 mg)
| pill_id =
| routes = Oral
| onset = LDL lowering at 1 week, max by 4 weeks
| duration = 24 hours
| halflife = ~19 hours<ref name="crestor-label">FDA Prescribing Information, Crestor (rosuvastatin calcium), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021366s039lbl.pdf</ref>
| bioavailability = ~20% (oral; hydrophilic, minimal CYP metabolism, mostly excreted unchanged in bile)<ref name="crestor-label" />
| pregnancy = Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021. Use individualized.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="rosuvastatin-mech-claim">Rosuvastatin is a hydrophilic competitive HMG-CoA reductase inhibitor; per milligram it is the most potent statin in current use, with substantial LDL-lowering at 5-10 mg.</vote> Minimal CYP3A4 dependence (CYP2C9 minor) reduces drug-drug interactions; transport in and out of hepatocytes is largely via OATP1B1, making SLCO1B1 PGx genotype the most clinically actionable marker for statin-associated myopathy<ref name="cpic-statin-slco1b1">CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 and Statin-Associated Musculoskeletal Symptoms, 2022. https://cpicpgx.org/guidelines/cpic-guideline-for-simvastatin-and-slco1b1/</ref>.
}}

== References ==
<references />

Rosuvastatin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #12